Cases That Test Your Skills

Manic after taking a vacation

Author and Disclosure Information

 

References

Mr. K is prone to motion sickness, and asks if he can take over-the-counter dimenhydrinate tablets for long car rides. He reports that dimenhydrinate has worked well for him in the past without triggering manic episodes, and he did not anticipate needing to take it very often.

What would you tell Mr. K about dimenhydrinate for motion sickness during car rides?
a) Mr. K should not take dimenhydrinate to prevent motion sickness because he experienced a manic episode triggered by a scopolamine patch
b) Mr. K can use dimenhydrinate as much as he wants to prevent motion sickness because it poses no risk of mania
c) Mr. K can use dimenhydrinate with caution and sparingly on a trial basis, as long as he is taking his mood stabilizer


FOLLOW UP Cautious use
The psychiatrist advised Mr. K to take dimenhydrinate cautiously when needed for long car rides. The psychiatrist feels this is safe because Mr. K is taking a mood stabilizer (lithium). Also, although dimenhydrinate has anticholinergic properties, occasional use is thought to pose less risk of triggering mania than the constant anticholinergic exposure over several days with a scopolamine patch. (The scopolamine patch contains 1.5 mg of the drug delivered over 3 days [ie, 0.5 mg/d]. In trials of IV scopolamine for depression, the dosage was 0.4 mcg/kg/d administered over 3 consecutive days.15-17 For an adult weighing 70 kg, this would be equivalent to 0.24 mg/d. Therefore, using a scopolamine patch over 3 days would appear to deliver a robust antidepressant-level dosage, even taking into account possible lower bioavailability with transdermal administration compared with IV infusion.)

The psychiatrist concludes that sporadic use of dimenhydrinate tablets for motion sickness during occasional long car rides poses less of a risk for Mr. K of triggering mania than repeat use of a scopolamine patch.


The author’s observations

Mr. K’s case is notable for several reasons:

  • Novelty. This might be the first report of scopolamine-induced mania in the literature. In clinical trials by Furey and Drevets,15 Drevets and Furey,16 and Ellis et al,17 no study participants who received scopolamine infusion developed mania or hypomania. Although it is possible that Mr. K’s manic episode could have occurred spontaneously and was coincidental to his scopolamine use, there are valid reasons why scopolamine could trigger mania in a vulnerable person.
  • Biochemical insight. The case underscores the role of the muscarinic cholinergic system in regulating mood.10
  • Rational medical care. Sensible clinical decision-making was needed when Mr. K asked about using dimenhydrinate for motion sickness during car rides. Although there might not be definitively correct answers for questions that arose during Mr. K’s care (in the absence of research literature), theoretical understanding of the antidepressant effects of anticholinergic medications helped inform the psychiatrist’s responses to Mr. K and his wife.

Bottom Line
Scopolamine, often applied via a transdermal patch to treat motion sickness, has some antidepressant effect, which could lead to mania in a person predisposed to mental illness. The drug’s action on central muscarinic cholinergic receptors could be responsible for its effect on mood. Mood stabilizers and stopping the offending agent are mainstay treatments for scopolamine-induced mania.

Related Resources
  • Furey ML, Zarate CA Jr. Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side effects. J Clin Psychiatry. 2013;74(8):850-851.
  • Khajavi D, Farokhnia M, Modabbernia A, et al. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(11):1428-1433.

Drug Brand Names
Clonazepam • Klonopin
Dimenhydrinate • Dramamine
Lithium • Eskalith, Lithobid
Quetiapine • Seroquel

Disclosure
Dr. Tan reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Pages

Recommended Reading

PSYCHIATRY UPDATE 2016
MDedge Psychiatry
Psychosis: First-episode variety in adolescence ‘insidious’
MDedge Psychiatry
Psychosis: Watch for sudden poor academic performance
MDedge Psychiatry
Brexpiprazole combined analysis shows schizophrenia safety, efficacy
MDedge Psychiatry
VIDEO: Lifestyle intervention blocks antipsychotic-associated weight gain
MDedge Psychiatry
Schizophrenia, psychotic disorders more likely in refugees
MDedge Psychiatry
The Germanwings tragedy: A look at the final report
MDedge Psychiatry
Patients with severe mental illness can benefit from cognitive remediation training
MDedge Psychiatry
When and why to initiate antipsychotic polypharmacy, and with which agents
MDedge Psychiatry
Be an activist to prevent edentulism among the mentally ill
MDedge Psychiatry